Perspectives of sevelamer in hyperphosphatemia treatment in patients with chronic kidney disease stage III-V


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Представлены подходы к коррекции гиперфосфатемии при хронической болезни почек III-V стадий с помощью севеламера гидрохлорида.

Full Text

Restricted Access

References

  1. Kidney Diseas: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evalution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).Kidney Int. 2009;76 (Suppl. 113): S1-S130.
  2. CKD and ESRD in the Elderly: Current Prevalence, Future Projections, and Clinical Significance Lesley A Stevens, Gautham Viswanathan, Daniel E Weiner.
  3. Adv Chronic Kidney Dis. Author manuscript; available in PMC 2011 August 23.
  4. Published in final edited form as: Adv Chronic Kidney Dis. 2010;17(4): 293-301.
  5. Zhang Qiu-Li., Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review BMC Public Health. 2008; 8:117.
  6. Милованова Л.Ю., Козловская Л.В., Милованов Ю.С. и др. Механизмыы нарушения фофсорно-кальциевого гомеостаза в развитии сердечнососудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (FGF-23) и klotho. Тер. арх. 2010; 6: 66-72.
  7. Милованова Л.Ю., Милованов Ю.С., Плотникова А.А. и др. Эктопическая минерализация при хронической болезни почек - механизмы, патогенез, современные возможности профилактики и лечения. Современная медицинская наука. 2012; 1: 16-33.
  8. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Российское диализное общество (май 2010). Нефрология и диализ. 2011;13(1): 33-51.
  9. Block G., Hulbert-Shearon T., Levin N. et al. Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998; 31: 607-617.
  10. Rodriguez-Benot A., Martin-Malo A., Alvarez-Lara M. et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am. J. Kidney. Dis., 2005; 46: 68-77.
  11. Томилина Н.А., Волгина Г.В., Бикбов Б.Т. и соавт. Проблема сердечнососудистых заболеваний при хронической почечной недостаточности. Нефрология и диализ. 2003;5(1): 43-49.
  12. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003; 16(2): 101-105.
  13. Милованова Л.Ю. Факторы риска сердечно-сосудистой летальности у больных хронической почечной недостаточностью на программном гемодиализе. Дисс. канд. мед. наук. М., 2005.
  14. Hruska K.A., Mathew S., Lund R., Qiu P., Pratt R. Kidney Int. Author manuscript; available in PMC 2009 August 31. Hyperphosphatemia of Chronic Kidney Disease. Kidney Int. 2008; 74(2):148-157.
  15. Gutiérrez O.M., Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. Circulation. 2009; 119: 2545-2552.
  16. Nakanishi S. et al. Serum FGF-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005; 68(1): 410-415.
  17. Milovanova L., Milovanov Y., Plotnikova A. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III-IV (Systematic Rewiew and Meta-Analysis). Chronic Kidney Disease and renal Transplantation. Ed. by Manisha Sahay. INTECH. 2012; 95-118.
  18. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Нарушения фосфорно-кальциевого обмена при хронической болезни почек III-V клиническая нефрология 5/6 - 2012 дом, может приводить к снижению общей летальности больных ХБП, однако для окончательного подтверждения этого суждения необходимы дальнейшие исследования. стадий. Клин. нефрол. 2011; 1: 58-68.
  19. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрол. диал.2002; 2(4): 113-117.
  20. Chertow G., Burke S., Raggi P, Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
  21. Block G., Spiegel D., Ehrlich J. et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
  22. Kakuta T., Tanaka R., Hyodo T. et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am.J.Kidney Dis. 2011; 57(3): 422-431
  23. Barretto D., Barreto F., de Carvalho A. et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BriC study. Nephron Clin. Pract. 2008; 110: 273-283.
  24. Qunibi W., Moustafa M.,Muenz L. et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control:the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am. J. Kidney Dis. 2008; 51: 952-965.
  25. Russo D., Miranda I., Ruocco C. et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007; 72: 1255-1261.
  26. Di Iorio B., Bellasi A., Russo D. On behalf of the INDEPENDENT Study Investigators Mortality in Kidney Disease patients Treated with PhosphateBinders:A Randomized Study. Clin. J. Am. Soc. Nephrol. 2012;7(3):487-493.
  27. Block G., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-441.
  28. Suki W., Zabaneh R., Cangiano J. et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-1137.
  29. St Peter W.L., Liu J., Weinhandl E. et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidney Dis. 2008; 51: 445-454.
  30. Borzecki A., Lee A., Wang S. et al. Survival in end stage renal disease:calcium carbonate vs. sevelamer. J. Clin. Pharm. Ther. 2007; 32: 617-624.
  31. Oliveira R.B., Cancela A.L.E., Graciolli F.G. et al. Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? Clin. J. Am. Soc. Nephrol. 2010; 5(2): 286-291.
  32. Gutiérrez O.M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008;359: 584-592.
  33. Vemuri N., Michelis M.F, Matalon A. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study. BMC Nephrol. 2011; 12: 49.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies